Letong Cai
YOU?
Author Swipe
View article: Disruption of cell-intrinsic PCSK9 enhances the antitumor efficacy of CD8<sup>+</sup> T cells
Disruption of cell-intrinsic PCSK9 enhances the antitumor efficacy of CD8<sup>+</sup> T cells Open
Background Tumor-derived proprotein convertase subtilisin/kexin type 9 (PCSK9) facilitates tumor progression, but the role of immune cell-intrinsic PCSK9 in tumor control remains unclear. Methods Orthotopic models of pancreatic cancer and …
View article: High percentage of bone marrow CD8+ tissue-resident-like memory T cells predicts inferior survival in patients with acute myeloid leukemia
High percentage of bone marrow CD8+ tissue-resident-like memory T cells predicts inferior survival in patients with acute myeloid leukemia Open
Tissue-resident memory T (TRM) cells infiltrating solid tumors could influence tumor progression and the response to immune therapies. However, the proportion and prognostic value of TRM cells in the bone marrow (BM) of patients with acute…
View article: High percentage of bone marrow CD8+ tissue-resident-like T cells predicts inferior survival in patients with acute myeloid leukemia
High percentage of bone marrow CD8+ tissue-resident-like T cells predicts inferior survival in patients with acute myeloid leukemia Open
Background Acute myeloid leukemia (AML) is a malignant clonal blood disease and the most common type of acute leukemia in adults. Despite continuous advances in treatments, the long-term prognosis of AML has not improved substantially. Tis…
View article: BCL11B promotes T‐cell acute lymphoblastic leukaemia cell survival via the XRCC5/C11ORF21 axis
BCL11B promotes T‐cell acute lymphoblastic leukaemia cell survival via the XRCC5/C11ORF21 axis Open
B-cell lymphoma/leukaemia 11B (BCL11B) is an essential transcriptional regulator of T cells and is engaged in regulating vital biological processes including T-cell development, proliferation, differentiation and survival.1, 2 Previous stu…
View article: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy Open
In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted therapies. However, not all cancer patients benefit from single o…